Form 4: OmniAb CEO Matthew Foehr Acquires Shares via RSU Vesting

OmniAb President and CEO Matthew Foehr acquired 36,459 shares through RSU vesting, with a mandatory portion sold to cover tax obligations.

Summary

• Matthew W. Foehr, President and CEO of OmniAb, Inc., vested 36,459 Restricted Stock Units (RSUs) on April 7, 2026.
• A total of 19,244 shares were sold at a weighted average price of $1.49 to satisfy tax withholding obligations.
• The sale was a non-discretionary 'sell-to-cover' transaction mandated by the company's equity incentive plan.
• Following these transactions, Mr. Foehr directly owns 4,420,492 shares of common stock.
• The reporting person still holds 309,376 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event because the CEO retained nearly half of the vested shares and maintains a very large overall equity position, despite the low share price at the time of the tax sale.

Positives

• The CEO maintains a substantial direct ownership stake of over 4.4 million shares, aligning interests with shareholders.
• The share sale was non-discretionary and specifically for tax purposes, rather than a lack of confidence in the company.
• The vesting schedule shows a long-term commitment, with grants vesting over a three-year period.

Negatives

• The weighted average sale price of $1.49 represents a relatively low valuation point for the equity sold.
• A significant portion (approximately 52.7%) of the vested shares was immediately sold to cover taxes.

Risks

• Market volatility may affect the value of the remaining 309,376 derivative securities held by the CEO.
• Concentrated ownership by management can influence corporate governance and decision-making.

Future Outlook

The reporting person continues to hold 309,376 RSUs which are subject to future vesting, suggesting continued service and performance alignment with the company's long-term goals.

Management Comments

• The sales were mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a sell-to-cover transaction and do not represent discretionary trades.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions are standard practice in the biotechnology and broader tech sectors, allowing executives to manage the significant tax liabilities triggered by RSU vesting without initiating a voluntary exit from their position.

Comparison to Industry Standards

• The use of a three-year vesting schedule is consistent with industry standards for mid-cap biotechnology firms like AbCellera or Ligand Pharmaceuticals.
• The sell-to-cover mechanism is a common automated governance feature used by many NASDAQ-listed companies to prevent insider trading concerns during tax events.

Related Party Transactions

• The reporting person is the President, CEO, and a Director of the company, and the transactions involve equity compensation granted by the company.

Stakeholder Impact

• Shareholders may see this as a sign of stability given the CEO's high level of retained ownership.
• The market receives transparency regarding executive compensation and tax-related selling activity.

Next Steps

• Remaining 309,376 RSUs will continue to vest according to the established annual schedule.

Key Dates

Recommendation

The filing reflects routine executive compensation activity and does not signal a change in company fundamentals or management's long-term outlook. The CEO's high retention of shares post-vesting supports a hold rating for investors monitoring insider activity.

Keywords

OmniAb, OABI, Matthew Foehr, Insider Trading, Form 4, RSU Vesting, Sell-to-Cover, Biotechnology, Executive Compensation